We took advantage of Elevance Health's share price weakness in the fourth quarter and added modestly to our investment. Click ...

Elevance Health reported nearly $6 billion in 2024 profits including $418 million in the fourth quarter as the health insurer worked to overcome rising medical expenses from patients in its ...

Operator instructions] As a reminder, today's conference is being recorded. I would now like to turn the conference over to ...

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx ...

Analysts' ratings for Elevance Health (NYSE:ELV) over the last quarter vary from bullish to bearish, as provided by 6 analysts. Summarizing their recent assessments, the table below illustrates ...

Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target is $463.00. Whit Mayo has given his Buy rating due ...

Elevance Health said Thursday it expects cost pressures on its Medicaid business to ease by midyear. That could spell good news for other Medicaid players as well. Medicaid managed care ...

Before making this announcement, Elevance Health was easily earning enough to cover the dividend. As a result, a large proportion of what it earned was being reinvested back into the business.

Elevance Health is happy with the performance of its commercial health insurance business, but not happy enough to take an optimistic approach to setting premiums. Elevance executives talked about ...

Elevance Health (NYSE:ELV) just dropped its Q4 earnings, and it's a mixed bag. Revenue climbed 6% to $45 billion, fueled by higher premium yields and a 19% surge in its Carelon division.